Cancer survivorship issues in older adults

Cancer Survivorship: Today and Tomorrow

Volumn , Issue , 2007, Pages 215-224

  Malek, Karim S ^a   Silliman, Rebecca A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62649167112     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-68265-5_16     Document Type: Chapter

References (125)

1. Ries L, Eisner M, Kosary C, et al. Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review 1975-2000. Vol. 2003; National Cancer Institute, 2003.
2. Ries L, Kosary C, Hankey B. SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999.
3. Miller B, Ries L, Hankey B, Kosary C, Edwards B. Cancer Statistics Review 1973-1989: National Cancer Institute, 1992.
4. Kennedy B, Bushhouse S, Benber A. Minnesota population cancer risks. Cancer 1994;73:724-729.
5. Mettlin C. New evidence of progress in the National Cancer Program. Cancer 1996;78:2043-2044.
6. Levi F, Vecchia CL, Lucchini F, et al. Worldwide trends in cancer mortality in the elderly, 1955-1992. Eur J Cancer 1996;32A: 652-672.
7. Vecchia CL, Levi F, Lucchini F, et al. International perspectives of cancer and aging. In: Balducci L, Lyman G, Ershler W (eds). Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publishers, 1998:19-93.
8. Sargent D, Goldberg R, Jacobson S, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097.
9. Schild S, Stella P, Geyer S, et al. The outcome of combinedmodality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206.
10. Silliman RA. What constitutes optimal care for older women with breast cancer? J Clin Oncol 2003;21:3554-3556.
11. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003;21:3580-3587.
12. Yee K, Pater J, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003;21:1618-1623.
13. Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Eng J Med 1999;341:2061-2067.
14. Monfardini S, Sorio R, Boes G, et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new drug development studies. Cancer 1995;76:333-338.
15. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-1389.
16. Current population reports, special studies: 65 in the United States. Washington, DC: US Bureau of the Census, 1996:2-8.
17. United States life tables, 2000. Natl Vital Stat Rep 2002;51:1-38.
18. Record high life expectancy. Stat Bull Metrop Insur Co 1993;74:28-35.
19. Moroff S, Pauker S. What to do when the patient outlives the literature, or DEALE-ing with a full deck. Medical Decision Making 1983;3:313-338.
20. Fried L, Wallace R. The complexity of chronic illness in the elderly: From clinic to community. In: Wallace R, Woolson R (eds). The Epidemiologic Study of the Elderly. New York: Oxford University Press, Inc, 1992:10-19.
21. Yancik R, Wesley M, Ries L. Comorbidity and age as predictors of risk for early mortality in male and female colon cancer patients: a population-based study. Cancer 1998;82:2123-2134.
22. Satariano W, Ragland D. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
23. Satariano W. Comorbidities and cancer. In: Hunter C, Johnson K, Muss H (eds). Cancer in the Elderly. New York: Dekker, 2000:477-499.
24. Mandeblatt J, Bierman A, Gold K, Silliman R. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res 2001;36: 1085-1107.
25. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
26. Wang P, Walker A, Tsuang M, Orav E, Levin R, Avron J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol 2000;53:571-578.
27. Monfardini S, Ferrucci L, Fratino L, Lungo ID, Serraino D, Zagonel V. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-401.
28. Reuben D. Principles of geriatric assessment. In: Hazzard W, Blass J, Ouslander J, Tinetti M (eds). Principles of Geriatric Medicine and Gerontology. New York: McGraw-Hill, 2003:99-110.
29. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt) 2000;14:221-227.
30. Moore AA, Siu AL. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument [see comment]. Am J Med 1996;100:438-443.
31. Chen H, Cantor A, Meyer J, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 2003;97:1107-1114.
32. Greenblatt D, Sellers E, Shader R. Drug therapy: drug disposition in old age. New Engl J Med 1982;306:1018-1028.
33. Shaw P. Common pitfalls in geriatric drug prescribing. Drugs 1982;23:324-328.
34. Beers M, Ouslander J. Risk factors in geriatric drug prescribing: a practical guide to avoid problems. Drugs 1989;37:105-112.
35. Yancik R, Havlik R, Wesley M. Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 1996;5:399-412.
36. Newschaffer C, Penberthy M, Lynne M, Desch C, Retchin S, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with non-metastatic breast cancer. Arch Intern Med 1996;156:85-90.
37. Fleming S, Pursley H, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care 2005;43:132-140.
38. West D, Satariano W, Ragland D. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Intern Med 1996;413-419.
39. Fleming S, Rastogi A, Dmitrienko A, Johnson K. A comprehensive index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999;37:601-614.
40. Yancik R, Wesley M, Ries M, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
41. Havlick R, Yancik R, Long S, et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74(suppl):2101-2106.
42. Silliman R, Lash T. Comparison of interview-based and medical record-based indices of comorbidity among breast cancer patients. Med Care 1999;37:339-349.
43. Deyo R, Cherkin D, Clol M. Adapting a clinical comorbidity index for use with ICD-9 CM-administrative databases. J Clin Epidemiol 1992;45:613-619.
44. Romano P, Roos L, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-1079.
45. Romano P, Roos L, Jollis J. Further evidence concerning the use of clinical comorbidity index with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1085-1090.
46. Small GW. Recognizing and treating anxiety in the elderly. J Clin Psychiatry. 1997;58:41-47; discussions 48-50.
47. Osborn DP, Fletcher AE, Smeeth L, et al. Factors associated with depression in a representative sample of 14217 people aged 75 and over in the United Kingdom: results from the MRC trial of assessment and management of older people in the community. Int J Geriatr Psychiatry. 2003;18:623-630.
48. Feinstein A. The pre-therapeutic classification of comorbidity in chronic diseases. J Chron Dis 1970;23:455-469.
49. Lash T, Thwin S, Horton N, Guadagnoli E, Silliman R. Multiple informants: a new method to assess comorbidity in breast cancer patients. Am J Epidemiol 2003;157:249-257.
50. Kaplan M, Feinstein A. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974;27:387-404.
51. Greenfield S, Blanco D, Elashoff R, Ganz P. Patterns of care related to age of breast cancer patients. JAMA 1987;257:2766-2770.
52. Bennett C, Greenfield S, Aronow H, Ganz P, Vogelzang N, Elashoff R. Patterns of care related to age of men with prostate cancer. Cancer 1991;67:2633-2441.
53. Lyman G. Decision analysis: a way of thinking about health care in the elderly. In: Balducci L, Lyman G, Ershler W (eds). Geriatric Oncology. Philadelphia: JB Lippincott, 1992:5-14.
54. Carney P, Miglioretti D, Yankaskas B, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-175.
55. Diab S, Elledge R, Clark G. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-556.
56. Walter L, Covinsky K. Cancer screening in elderly patients. A framework for individualized decision making. JAMA 2001;285: 2750-2756.
57. Law M. Screening without evidence of efficacy [see comment]. BMJ 2004;328:301-302.
58. Rosenthal RA, Zenilman ME, Katlic MR (eds). Principles and Practice of Geriatric Surgery. New York: Springer-Verlag, 2001.
59. Pofahl WE, Pories WJ. Current status and future directions of geriatric general surgery. J Am Geriatr Soc 2003;51:S351-S354.
60. Devereaux E, Kemeny M. Surgery in the elderly oncology patient. In: Hunter C, Johnson K, Muss H (eds). Cancer in the Elderly. New York: Dekker, 2000:153-186.
61. Evans B, Townsend C, Thompson J. Organ physiology of aging. Surg Clin North Am 1994;74:23-29.
62. Wynne H, Cope L, Mutch E, et al. The effect of aging upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;1989:297-301.
63. Mooney H, Roberts R, Cooksley W, et al. Alterations in the liver with ageing. Clin Gastroenterol 1985;14:757-771.
64. Rocca R. Psychosocial aspects of surgical care in the elderly patient. Surg Clin North Am 1994;74:223-243.
65. Fleisher L, Eagle K. Lowering cardiac risk in non-cardiac surgery. N Engl J Med 2001;345:1677-1682.
66. Marcello P, Roberts P. "Routine" preoperative studies: which studies in which patients? Surg Clin North Am 1996;76:11-23.
67. Velanovich V. Preoperative laboratory evaluation. J Am Coll Surg 1996;183:79-87.
68. Kaplan E, Sheiner L, Boeckmann A, et al. The usefulness of preoperative laboratory screening. JAMA 1985;253:3576-3581.
69. Roizen M, Kaplan E, Schreider B, et al. The relative roles of the history and physical examination, and laboratory testing in preoperative evaluation for outpatient surgery: the "Starling" curve of preoperative laboratory testing. Anesthesiol Clin North Am 1987;5:15.
70. Goldman L, Caldera D, Nussbaum S. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845-850.
71. Goldman L. Cardiac risks and complications of noncardiac surgery. Ann Intern Med 1983;98:504-513.
72. Owens W, Felts J, Jr. ES. ASA physical status classifications: a study of consistency of ratings. Anesthesiology 1978;49:239-243.
73. Evans T. Hemodynamic and metabolic therapy in critically ill patients. N Engl J Med 2001;345:1417-1418.
74. Cooper A, Doig G, Sibbald W. Pulmonary artery catheters in the critically ill: an overview using the methodology of evidencebased medicine. Crit Care Clin 1996;12:777-794.
75. Sandman J, Hull R, Brant R, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5-14.
76. Tobias J. Clinical practice of radiotherapy. Lancet 1992;339: 159-163.
77. Sargent E, Burns F. Repair of radiation-induced DNA damage in rat epidermis as function of age. Rad Res 1985;102:176-181.
78. Scalliet P, Pignon T. Radiotherapy in the elderly. In: Balducci L, Lyman G, Ershler W (eds). Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publishers, 2000;421-427.
79. Mundt A. Radiation therapy and the elderly. In: Hunter C, Johnson K, Muss H (eds). Cancer in the Elderly. New York: Dekker, 2000:187-216.
80. Isenring E, Bauer J, Capra S. The scored Patient-generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy. Eur J Clin Nutr 2003;57:305-309.
81. Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54:462-470.
82. Janda M, Johnson D, Woelfl H, et al. Measurement of quality of life in head and neck cancer patients utilizing the quality of life radiation therapy questionnaire. Strahlenther Onkol 2002;178:153-158.
83. Berg C, Carbone P. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-1992.
84. Christman K, Muss H, Case L, et al. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA 1992;268:57-62.
85. Lichtman S, Skirvin J, Vemulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Clin Rev Oncol Hematol 2003;46:101-114.
86. Yuen G. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990;6:257-267.
87. Wallace S, Whiting B. Factors affecting drug binding in plasma of elderly patients. Br J Clin Pharmacol 1976;3:327-330.
88. Woodhouse K, Wynne H. Age-related changes in liver size and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1998;15:287-294.
89. Soteniemi E, Arranto A, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-339.
90. Vestal R. Aging and pharmacology. Cancer 1997;80:1302-1310.
91. Lindeman R, Tobin J, Shock N, et al. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-285.
92. Cockroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-42.
93. Lipschitz D. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995;22(suppl):3-5.
94. Ibrahim N, Frye D, Buzdar A, et al. Docorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med 1996;156:882-888.
95. Fisher R, Graynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
96. Lyman G, Kuderer D, Djulbegovic B. Prophylactic granulocyte colony-stimulating factors in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112: 406-411.
97. Balducci L, Lyman G. Patients aged ?70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 2001;19:1583-1585.
98. Ozer H, Armitage J, Bennett C, et al. 2000 Update of recommendations for the use of Hematopoietic Colony-Stimulating Factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-3585.
99. Chavez P, Volpato S, Fried L. Challenging the World Health Organization criteria for anemia in older women. J Am Geriatr Soc 2001;49 (suppl 3):10.
100. Izaks G, Westendorp R, Knoot D. The definition of anemia in older persons. JAMA 1999;281:1714-1717.
101. Kikuchi M, Inagaki T, Shinagawa N. Five-year survival of older people with anemia: variation with hemoglobin concentration. J Am Geriatr Soc 2001;49:1226-1228.
102. Gutstein H. The biologic basis of fatigue. Cancer 2001;92 (suppl):1678-1683.
103. Nissenson A. Epoetin and cognitive function. Am J Kidney Dis 1992;20 (suppl):21-24.
104. Shrijvers D, Highley M, Bruyn ED, et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999;10:147-153.
105. Rizzo J, Lichtin A, Woolf S, et al. Use of Epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;19:4083-4107.
106. Hellstrom-Lindberg E, Ahlgren T, Begguin Y, et al. Treatment of the anemia of myelodysplastic syndromes with G-CSF plus erythoropoietin: Results of a randomized phase II study and long term follow-up of 71 patients. Blood 1998;92:68-75.
107. Popescu R, Norman A, Ross P, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
108. Sargent D, Goldberg R, MacDonald J, et al. Adjuvant chemotherapy for colon cancer (CC) is beneficial without significant incrased toxicity in elderly patients (Pts): results from 3351 Pt meta-analysis [Abstract 933]. Proc Am Soc Clin Oncol 2000;19: 241a.
109. Cancer control and population sciences: research findings. http://dccps.nci.nih.gov/ocs/prevalence. Accessed August 1, 2005.
110. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implication of age and aging on US cancer burden. Cancer 2002;94:2766-2792.
111. National Center for Health Statistics. Life Tables of the United States, 1997.
112. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol 2003;58: 82-91.
113. Stafford RS, Cyr PL. The impact of cancer on the physical function of the elderly and their utilization of health care. Cancer 1997;80:1973-1980.
114. Smith TJ, David NE, Schapira DV, et al: American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;47:1080-1082.
115. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: follow-up after treatment for breast cancer. Can Med Assoc J 1998;158(S3):S65-S70.
116. Report from the National Breast Cancer Consensus Conference. Management of newly diagnosed early breast cancer: A national approach to breast cancer control. Med J Aust 1994;161(S7): S10-S16.
117. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 1994;271:1587-1592.
118. Roselli Del Turco M, Palli D, Criddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. JAMA 1994;271: 1593-1597.
119. Shapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA 1991;265:380-382.
120. Schapira MM, McAulliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care 2000;38:281-289.
121. Lash TL, Silliman RA. Medical surveillance after breast cancer diagnosis. Med Care 2001;39:945-955.
122. Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, van Walraven C, et al. Surveillance mammography after treatment of primary breast cancer. A systematic review. Breast 2002;11: 228-235.
123. Westrup JL, Lash TL, Thwin SS, Silliman RA. Risk of decline in upper-body function and symptoms among older breast cancer patients. J Gen Intern Med; under review.
124. Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol 1998;53A:M372-M378.
125. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of nonbreast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003;21:1447-1451.